AIT effectiveness on asthma progression
Progression of asthma was analysed for asthmatic patients at baseline. With 17.8%, significantly more patients treated with MCT®-associated allergoids did not receive prescriptions for symptomatic asthma medication in the follow up period vs. control group (OR: 0.48; p = 0.004). Significant differences were also shown for the treatment group of allergoid 2 (16.2%, OR: 0,47; p < 0.001) and allergoid 3 (14.3%, OR: 0.48; p < 0.001) and therefore for the entire AIT treatment group (15.6%, OR: 0.48; p < 0.001, see Figure 3a).
In addition, the prescriptions of symptomatic asthma medication in the MCT®-associated allergoid treatment group were significantly reduced by 35.6% in the follow-up vs. baseline and control group (p < 0.001). These effects could also be demonstrated for the allergoid 2, allergoid 3 and entire AIT treatment group (28.3%, 30.1%, 29.1%, p < 0.001, see Table 2).